Powder: -20°C for 3 years | In solvent: -80°C for 1 year
ACT-389949 is a potent and selective agonist of formyl peptide receptor type 2 (FPR2)/Lipoxin A4 receptor (ALX), with an EC50 of 3 nM for FPR2/ALX internalization into monocytes. It has the potential for the treatment of inflammatory disorders.
パッケージサイズ | 在庫状況 | 単価(税別) | |||
---|---|---|---|---|---|
サンプルについてお問い合わせ | |||||
1 mg | 在庫あり | ¥ 37,500 | |||
5 mg | 在庫あり | ¥ 79,500 | |||
10 mg | 在庫あり | ¥ 112,500 | |||
25 mg | 在庫あり | ¥ 180,500 | |||
50 mg | 在庫あり | ¥ 250,500 | |||
100 mg | 在庫あり | ¥ 340,000 |
説明 | ACT-389949 is a potent and selective agonist of formyl peptide receptor type 2 (FPR2)/Lipoxin A4 receptor (ALX), with an EC50 of 3 nM for FPR2/ALX internalization into monocytes. It has the potential for the treatment of inflammatory disorders. |
ターゲット&IC50 | FPR2/ALX:3 nM(EC50) |
In vivo | ACT-389949 demonstrates a favorable tolerance profile. Peak concentration levels occur approximately 2 hours post-administration, and it exhibits a mean terminal half-life of 29.3 hours. The administration of ACT-389949 induces a dose-dependent, prolonged internalization of FPR2/ALX within leukocytes [1]. |
分子量 | 428.39 |
分子式 | C20H18F2N6O3 |
CAS No. | 1258417-54-7 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 10 mg/mL (23.34 mM), when pH is adjusted to 1 with HCl. Sonication is recommended.
You can also refer to dose conversion for different animals. 詳細
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
ACT-389949 1258417-54-7 Others inhibit ACT389949 ACT 389949 Inhibitor inhibitor